Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Publ. Version/Full Text
Research data
DOI
PMC
 |
Open Access Gold (Paid Option) |
|
as soon as is submitted to ZB.
Gene therapy targeting the blood-brain barrier improves neurological symptoms in a model of genetic MCT8 deficiency.
Brain 145, 4264-4274 (2022)
Publ. Version/Full Text
Research data
DOI
PMC
A genetic deficiency of the solute carrier monocarboxylate transporter 8 (MCT8), termed Allan-Herndon-Dudley syndrome, is an important cause of X-linked intellectual and motor disability. MCT8 transports thyroid hormones across cell membranes. While thyroid hormone analogues improve peripheral changes of MCT8 deficiency, no treatment of the neurological symptoms is available so far. Therefore, we tested a gene replacement therapy in Mct8- and Oatp1c1-deficient mice as a well-established model of the disease. Here, we report that targeting brain endothelial cells for Mct8 expression by intravenously injecting the vector AAV-BR1-Mct8 increased tri-iodothyronine (T3) levels in the brain and ameliorated morphological and functional parameters associated with the disease. Importantly, the therapy resulted in a long-lasting improvement in motor coordination. Thus, the data support the concept that MCT8 mediates the transport of thyroid hormones into the brain and indicate that a readily accessible vascular target can help overcome the consequences of the severe disability associated with MCT8 deficiency.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Thyroxine ; Tri-iodothyronine ; Cretinism ; Myelination ; Hypothyroidism
ISSN (print) / ISBN
0006-8950
e-ISSN
1460-2156
Journal
Brain: A Journal of Neurology
Quellenangaben
Volume: 145,
Issue: 12,
Pages: 4264-4274
Publisher
Oxford University Press
Non-patent literature
Publications
Reviewing status
Peer reviewed
Grants
Deutsche Forschungsgemeinschaft